Ignite Creation Date:
2024-05-06 @ 12:08 AM
Last Modification Date:
2024-10-26 @ 10:45 AM
Study NCT ID:
NCT01494415
Status:
UNKNOWN
Last Update Posted:
2015-12-15
First Post:
2011-12-14
Brief Title:
Concurrent Nab-PCarboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
Sponsor:
First Peoples Hospital of Hangzhou
Organization:
First Peoples Hospital of Hangzhou
Study Overview
Official Title:
A Phase II Study of Concurrent Nab-Paclitaxel Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer
Status:
UNKNOWN
Status Verified Date:
2015-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer especially for squamous cell cancer The regimen of weekly nab-paclitaxel carboplatin and concurrent radiotherapy was well tolerated in a phase I study Given nab-paclitaxel carboplatin and concurrent radiotherapy in patients with local advanced squamous cell lung cancer may have promising result
Detailed Description:
This study was conducted to explore the efficacy and toxicity of concurrent chemoradiotherapy with nab-paclitaxel carboplatin and thoracic radiotherapy in unresectable local advanced squamous cell lung cancer Patients will be given nab-paclitaxel weekly at a dose of 60mgm2 in combination with carboplatin AUC 2 weekly during concurrent chemoradiotherapy Thoracic radiation was administered at a dose of 66 Gy33 fractions both 3 dimensional conformal and intensity modulated radiation therapy are allowed Two cycles of consolidation therapy with full dose nab-paclitaxel 260 mgm2 on day 1 and carboplatin AUC 6 on day 1 every 21 day will be delivered
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None